Horizon Therapeutics Plc

HZNP

$109.06

+10.7% last 12 months

George Soros Holding value: $312 Million Ken Griffin Holding value: $298 Million Jim Simons Holding value: $183 Million Ray Dalio Holding value: $18.1 Million Jeremy Grantham Holding value: $4.83 Million Joel Greenblatt Holding value: $4.27 Million Mario Gabelli Holding value: $2.55 Million Steven Cohen Holding value: $0

Market Cap

$25.1 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$57.84 - $117.49

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

48.21x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $25.1 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $25.4 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $0.00 (0.0%)
1 Year Return Profit or loss of share price change plus dividend yield. +10.7%
52-Week High Highest share price in the last 52 weeks. $117.49
52-Week Low Lowest share price in the last 52 weeks. $57.84
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.0
Outstanding Shares The number of shares the company has issued and are held by stockholders. 228 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 1.66 Million

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 48.21
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. -158.21
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $2.22
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 7.27
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 4.96
Enterprise Value to Revenue Enterprise value divided by revenue 6.99
Enterprise Value to EBIT Enterprise Value divided by EBIT 36.6
Total Debt to Enterprise Value Total debt divided by enterprise value 0.1
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.51

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $3.63 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $2.71 Billion
EBIT Earnings before tax and interest payments. $693 Million
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $521 Million
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 14.37%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -30.5%
Return on Equity Equity divided by market cap. 10.28%
Return on Assets Indicates a company's profitability in relation to its total assets. 5.72%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 8.48%

Insider trades

No purchases

80,283.0 shares sold (8 transactions)

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q2 2022 Q3 2022 Q4 2022 Q1 2023

Similar stocks

AMGEN Inc.
AMGEN Inc.
Astrazeneca plc - ADR
Astrazeneca plc - ADR
Radius Health Inc.
Radius Health Inc.
Pfizer Inc.
Pfizer Inc.
Dr. Reddy`s Laboratories Ltd. - ADR
Dr. Reddy`s Laboratories Ltd. - ADR
Merck & Co Inc
Merck & Co Inc

News

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $7,500 Today

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $7,500 Today

Horizon Therapeutics (NASDAQ: HZNP ) has outperformed the market over the past 5 years by 42.39% on an annualized basis producing an average annual return of...

Benzinga Benzinga, 5 days ago
Horizon Therapeutics plc: New Analysis of MRI Findings Show UPLIZNA (inebilizumab-cdon) Reduced the Formation of Asymptomatic Optic Nerve Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Horizon Therapeutics plc: New Analysis of MRI Findings Show UPLIZNA (inebilizumab-cdon) Reduced the Formation of Asymptomatic Optic Nerve Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new MRI imaging data from the Phase 3 clinical trial showing UPLIZNA reduced the ...

Finanz Nachrichten Finanz Nachrichten, 6 days ago
Amgen upgraded at Wells Fargo citing a post-Horizon deal opportunity

Amgen upgraded at Wells Fargo citing a post-Horizon deal opportunity

Amgen (AMGN) traded higher Monday morning as Wells Fargo upgraded, citing an opportunity after the company''s $28B deal to acquire Horizon Therapeutics (HZNP...

Seeking Alpha Seeking Alpha, 7 days ago
Horizon Therapeutics plc: Real-World Experience Shows TEPEZZA (teprotumumab-trbw) Was Effective in Treating People With Dysthyroid Optic Neuropathy (DON)

Horizon Therapeutics plc: Real-World Experience Shows TEPEZZA (teprotumumab-trbw) Was Effective in Treating People With Dysthyroid Optic Neuropathy (DON)

-- Data presented at the North American Neuro-Ophthalmology Society (NANOS) Annual Meeting on March 11-16 in Orlando -- Horizon Therapeutics plc (Nasdaq: HZN...

Finanz Nachrichten Finanz Nachrichten, 8 days ago
Never miss a trade
To improve your user experience we use cookies.